文献速递其他结缔组织病

抗CD19 CAR-T细胞疗法作为自体造血干细胞移植后复发系统性硬化症的挽救治疗:病例系列

Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous haematopoietic stem cell transplantation: a case series.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

该病例系列评估抗CD19 CAR-T疗法作为自体造血干细胞移植(AHSCT)后复发系统性硬化症(SSc)挽救治疗的可行性、疗效和安全性。3例女性患者接受FMC63-28-CD3ζ CAR-T细胞输注,2例临床反应良好(FVC改善≥10%、mRSS降低≥25%),1例无CAR-T扩增且无临床反应。不良事件轻微,仅1级细胞因子释放综合征和1例管路相关血栓。

要点

  • 抗CD19 CAR-T疗法在AHSCT后复发SSc患者中耐受性良好,2/3例显示临床和影像学改善。
  • 1例患者无CAR-T扩增且无临床反应,提示可行性问题需进一步机制研究。
  • 不良事件轻微,仅1级细胞因子释放综合征和1例管路相关血栓,无长期血液学毒性。

核心结论

  • 抗CD19 CAR-T疗法在AHSCT后复发SSc患者中耐受性良好,并与临床和影像学改善相关。
  • 1例患者无CAR-T扩增且无临床反应,提示可行性问题需进一步机制研究。

研究设计与样本

  • 复发定义为mRSS增加≥25%或FVC下降≥10%。
  • 患者接受自体FMC63-28-CD3ζ CAR-T细胞(0.6×10^6/kg)输注,预处理为氟达拉滨(总量75 mg/m2)和环磷酰胺(900 mg/m2)。
  • 评估临床、功能和定量CT结局,随访12个月。

主要发现

  • 2例患者临床反应良好:FVC改善≥10%、mRSS降低≥25%,CT显示磨玻璃影减少。
  • 1例患者无CAR-T扩增,相应无临床反应。
  • 不良事件轻微:仅1级细胞因子释放综合征和1例管路相关血栓,无长期血液学毒性。

关键数值与推荐

  • 复发定义:mRSS增加≥25%或FVC下降≥10%。
  • CAR-T细胞剂量:0.6×10^6/kg;预处理:氟达拉滨总量75 mg/m2、环磷酰胺900 mg/m2。
  • 临床反应标准:FVC改善≥10%且mRSS降低≥25%。

临床怎么用

  • 对于AHSCT后复发的SSc患者,抗CD19 CAR-T疗法可能是一种可行的挽救治疗选择,但需监测CAR-T扩增情况。

局限性

  • 样本量小(3例),为单中心病例系列,结论需更大规模研究验证。
  • 1例患者无CAR-T扩增,提示可行性问题需进一步机制研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Autologous haematopoietic stem cell transplantation (AHSCT) is an established therapy for diffuse progressive systemic sclerosis (DpSSc), improving progression-free and overall survival compared with cyclophosphamide; however, relapse occurs in ∼12-17% of patients. Chimeric antigen receptor T cell (CAR-T) therapy offers a novel approach to deplete autoreactive B cells. This study aimed to assess the feasibility, efficacy and safety of anti-CD19 CAR-T therapy as a rescue treatment in patients with SSc relapse following AHSCT. METHODS: Thirty SSc patients underwent AHSCT at our centre over the past decade. Relapse was defined as an increase in modified Rodnan skin score (mRSS) ≥25% or a decrease in forced vital capacity (FVC) ≥10%. Three female patients (mean age 50 ± 13 years) relapsed after a mean of 2.8 ± 3.6 years. They received autologous FMC63-28-CD3ζ CAR-T cells (0.6 × 106/kg) following lymphodepletion with fludarabine (75 mg/m2 total) and cyclophosphamide (900 mg/m2). Clinical, functional and quantitative CT outcomes were assessed over 12 months. RESULTS: Two patients had a favourable clinical response with FVC improvement (≥10%) and ≥25% reduction in mRSS, accompanied by reduced ground-glass opacities on CT. One patient showed no CAR-T expansion and accordingly no clinical response. Adverse events were mild, limited to grade 1 cytokine release syndrome and one line-related thrombosis, without long-term haematological toxicity. CONCLUSION: Anti-CD19 CAR-T therapy was well tolerated and associated with clinical and radiological improvement in SSc patients relapsing after AHSCT. However, the absence of CAR-T expansion in one patient raises concerns regarding feasibility and warrants further mechanistic investigation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Rimar D, David P, Jacoby E, et al. Anti-CD19 CAR-T cell therapy as rescue treatment in systemic sclerosis relapsing after autologous haematopoietic stem cell transplantation: a case series. Rheumatology (Oxford). 2026. PMID: 41936079. doi:10.1093/rheumatology/keag173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。